Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19347136 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | October 2025 | March 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19242226 | Hyaluronidase Enzyme Formulations for High Volume Administration | June 2025 | January 2026 | Allow | 7 | 1 | 1 | No | No |
| 19212294 | STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLES | May 2025 | October 2025 | Allow | 5 | 1 | 1 | No | No |
| 18940001 | Hyaluronidase Enzyme Formulations for High Volume Administration | November 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18940031 | Hyaluronidase Enzyme Formulations for High Volume Administration | November 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18937712 | HYDROGENOPHILUS BACTERIUM TRANSFORMANT | November 2024 | July 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18935987 | FOOD COMPOSITION CONTAINING NOVEL ALDEHYDE DEHYDROGENASE FOR IMPROVING MEMORY AND COGNITIVE FUNCTION | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18882341 | CELL WALL HYDROLASES TARGETING C. ACNES | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18814865 | DEAMINASES AND VARIANTS THEREOF FOR USE IN BASE EDITING | August 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18781694 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | July 2024 | April 2025 | Allow | 9 | 1 | 1 | No | No |
| 18778981 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | July 2024 | January 2026 | Allow | 18 | 1 | 1 | No | No |
| 18767461 | SYSTEM AND METHOD FOR CO2 HYDROGENATION USING MULTI-ENZYME IMMOBILIZATION ON MODIFIED METAL-ORGANIC FRAMEWORK (MOF) | July 2024 | February 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18762259 | COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION | July 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18749788 | USE OF MUTANT OF IMMUNOGLOBULIN DEGRADING ENZYME IDEE | June 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18672113 | VERSATILE PEROXIDASES AND USES THEREOF | May 2024 | January 2025 | Allow | 8 | 1 | 1 | No | No |
| 18649712 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | April 2024 | October 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18642135 | Hyaluronidase Enzyme Formulations for High Volume Administration | April 2024 | October 2025 | Allow | 18 | 1 | 1 | No | No |
| 18620636 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY | March 2024 | March 2026 | Allow | 23 | 1 | 1 | Yes | No |
| 18609276 | MATERIALS AND METHODS FOR PROTEIN PRODUCTION | March 2024 | September 2025 | Allow | 18 | 1 | 1 | No | No |
| 18606664 | Enzymatic Methods for Treating Neurodegenerative Disorders | March 2024 | November 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18605166 | PROCESS FOR THE MANIPULATION OF NUCLEIC ACIDS | March 2024 | June 2025 | Allow | 15 | 0 | 1 | No | No |
| 18433433 | METHOD FOR CYCLIC BIOCHEMICAL CONVERSION OF CARBON DIOXIDE AND HOT GAS COGENERATION IN DEPLETED OIL AND GAS RESERVOIR | February 2024 | February 2025 | Allow | 12 | 2 | 0 | No | No |
| 18433161 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | February 2024 | February 2025 | Allow | 13 | 2 | 1 | No | No |
| 18395001 | Hyaluronidase Enzyme Formulations for High Volume Administration | December 2023 | October 2024 | Allow | 10 | 3 | 1 | Yes | No |
| 18524651 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | November 2023 | August 2024 | Abandon | 9 | 0 | 1 | No | No |
| 18561258 | ENHANCING FORMATION OF HUMAN MILK OLIGOSACCHARIDES (HMOS) BY MODIFYING LACTOSE IMPORT IN THE CELL | November 2023 | December 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18508594 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | November 2023 | February 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18382850 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | October 2023 | August 2025 | Allow | 22 | 1 | 1 | No | No |
| 18555377 | Tissue Modifier And Uses Therefor | October 2023 | December 2024 | Allow | 14 | 3 | 0 | Yes | No |
| 18469401 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | September 2023 | September 2024 | Abandon | 12 | 0 | 0 | No | No |
| 18550209 | PURIFICATION OF SIALOOLIGOSACCHARIDES | September 2023 | February 2025 | Allow | 17 | 3 | 1 | No | No |
| 18339050 | MICROORGANISMS AND METHODS FOR THE CONTINUOUS PRODUCTION OF ETHYLENE FROM C1-SUBSTRATES | June 2023 | July 2025 | Abandon | 25 | 3 | 1 | Yes | No |
| 18338958 | MICROORGANISMS AND METHODS FOR THE CONTINUOUS CO-PRODUCTION OF TANDEM REPEAT PROTEINS AND CHEMICAL PRODUCTS FROM C1-SUBSTRATES | June 2023 | May 2025 | Allow | 23 | 3 | 1 | Yes | No |
| 18333393 | BIOCATALYSTS FOR THE PREPARATION OF HYDROXY SUBSTITUTED CARBAMATES | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18317548 | ANTI-MICROBIAL AND UV-PROTECTIVE EXTRACTS AND METHODS OF MAKING AND USING THEREOF | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18308301 | SPLIT INTEIN MEDIATED PROTEIN POLYMERIZATION FOR MICROBIAL PRODUCTION OF MATERIALS | April 2023 | January 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18302932 | BIOSYNTHETIC PRODUCTION OF STEVIOL GLYCOSIDES AND PROCESSES THEREFORE | April 2023 | July 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18187249 | UV-RESISTANT BIOLOGICAL DEVICES AND EXTRACTS AND METHODS FOR PRODUCING AND USING THE SAME | March 2023 | April 2025 | Allow | 25 | 1 | 1 | No | No |
| 18186303 | UDP-GLYCOSYLTRANSFERASES | March 2023 | April 2025 | Allow | 25 | 3 | 0 | No | No |
| 18116810 | NOVEL NICOTINE DEGRADING ENZYME VARIANTS | March 2023 | April 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | February 2023 | January 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18165045 | MUTATED HISTIDINE DECARBOXYLASE AND USE THEREOF | February 2023 | August 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18105587 | MODIFIED BACTERIAL PROTEIN EXPRESSION SYSTEM | February 2023 | October 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18018360 | METHOD FOR PURIFYING (-)-AMBROX | January 2023 | July 2025 | Allow | 30 | 5 | 1 | Yes | No |
| 18099723 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | January 2023 | June 2025 | Allow | 29 | 1 | 0 | No | No |
| 17993441 | In vivo synthesis of sialylated compounds | November 2022 | April 2025 | Allow | 28 | 2 | 0 | No | No |
| 17926440 | ACE2 MUTEINS AND METHODS OF USING THE SAME | November 2022 | March 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 17976303 | PRETREATMENT OF LIGNOCELLULOSE USING TWO STAGE ALKALI AND MECHANICAL REFINING PROCESSES | October 2022 | April 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17976580 | METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18046295 | CARBOXYESTERASE BIOCATALYSTS | October 2022 | January 2025 | Allow | 27 | 2 | 1 | No | No |
| 17951048 | ENZYMATICALLY SYNTHESIZED OMEGA-3 STRUCTURED PHOSPHOLIPIDS | September 2022 | April 2025 | Allow | 31 | 4 | 1 | No | No |
| 17934025 | INNOVATIVE METHOD FOR IMPROVING ENZYME ACTIVITY OF NMN BIOSYNTHETIC ENZYME NAMPT | September 2022 | November 2024 | Allow | 26 | 3 | 1 | Yes | No |
| 17819086 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | August 2022 | August 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17818258 | ENGINEERED RIBOSOMAL PROMOTERS FOR PROTEIN PRODUCTION IN MICROORGANISMS | August 2022 | April 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17815059 | Production of desaturated fatty alcohols and desaturated fatty acyl acetates in yeast | July 2022 | August 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17790444 | GLUCOSE-6-PHOSPHATE DEHYDROGENASE MUTANT AND USE THEREOF IN PREPARING DETECTION REAGENT | June 2022 | November 2025 | Allow | 40 | 1 | 2 | No | No |
| 17844351 | TRUNCATED HYALURONAN SYNTHASE AND POLYNUCLEOTIDE ENCODING THE SAME | June 2022 | December 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17787493 | CONTINUOUS BIOPRODUCTION BY DECOUPLING GROWTH AND PRODUCTION | June 2022 | March 2026 | Allow | 45 | 1 | 1 | No | No |
| 17843741 | YEAST STRAINS EXHIBITING PROLONGED PERSISTENCE DURING A PLURALITY OF FERMENTATION CYCLES | June 2022 | April 2025 | Allow | 34 | 3 | 1 | No | No |
| 17806046 | BIOLOGICAL PROCESSES FOR THE PRODUCTION OF ARYL SULFATES | June 2022 | April 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17750276 | GENERATION OF ACYL ALCOHOLS | May 2022 | June 2024 | Allow | 25 | 1 | 1 | No | No |
| 17663631 | ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE N | May 2022 | January 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17660312 | CARBON CAPTURE IN FERMENTATION FOR COMMODITY CHEMICALS | April 2022 | August 2024 | Abandon | 28 | 2 | 1 | No | No |
| 17726387 | BIOCONVERSION OF 4-COUMARIC ACID TO RESVERATROL | April 2022 | April 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17723178 | Oral Care Compositions and Methods for Increasing the Stability of the Same | April 2022 | November 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17657307 | ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE C | March 2022 | January 2024 | Allow | 21 | 1 | 0 | No | No |
| 17701625 | BIOSYNTHETIC METHODS FOR THE MODIFICATION OF CANNABINOIDS | March 2022 | October 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17692254 | NOVEL URETHANASES FOR THE ENZYMATIC DEGRADATION OF POLYURETHANES | March 2022 | April 2025 | Allow | 37 | 3 | 0 | Yes | No |
| 17688900 | SIALYLTRANSFERASES AND USES THEREOF | March 2022 | January 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17668859 | Prehydrolysate Fermentability in Biomass Pretreatment | February 2022 | July 2025 | Allow | 41 | 3 | 1 | No | No |
| 17668360 | Second Additional Phytase Variants and Methods | February 2022 | July 2025 | Allow | 41 | 3 | 1 | Yes | No |
| 17666092 | PROCESSES FOR RECOVERING PRODUCTS FROM A CORN FERMENTATION MASH | February 2022 | January 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17631003 | MULTIKINASE DEGRADERS | January 2022 | September 2025 | Allow | 43 | 0 | 1 | No | No |
| 17629016 | FLAVIN MONONUCLEOTIDE-BINDING PROTEIN VARIANTS HAVING IMPROVED FLUORESCENCE INTENSITY DERIVED FROM ARABIDOPSIS THALIANA | January 2022 | February 2026 | Allow | 48 | 1 | 1 | No | No |
| 17575279 | KINETIC EXCLUSION AMPLIFICATION OF NUCLEIC ACID LIBRARIES | January 2022 | August 2025 | Allow | 43 | 1 | 0 | No | No |
| 17646773 | HEPARIN SKELETON SYNTHASE AND ITS MUTANTS AND APPLICATION | January 2022 | November 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17624373 | PHOTOACTIVATED ADENYLYL CYCLASE | January 2022 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17566373 | GENE MINING METHOD COMBINING FUNCTIONAL SEQUENCE AND STRUCTURE SIMULATION, NADH-PREFERRING PHOSPHINOTHRICIN DEHYDROGENASE MUTANT AND APPLICATION THEREOF | December 2021 | November 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17560753 | ALKANE OXIDATION BY MODIFIED HYDROXYLASES | December 2021 | November 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17556555 | METHODS AND ENZYME CATALYSTS FOR THE SYNTHESIS OF NON-CANONICAL AMINO ACIDS | December 2021 | February 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17620887 | ENHANCED PLATFORMS FOR UNNATURAL AMINO ACID INCORPORATION IN MAMMALIAN CELLS | December 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17621214 | BIOSYNTHESIS OF ENZYMES FOR USE IN TREATMENT OF MAPLE SYRUP URINE DISEASE (MSUD) | December 2021 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17555350 | GUANIDINE DEGRADATION ENZYME AND METHODS OF USE | December 2021 | July 2025 | Allow | 43 | 3 | 1 | No | No |
| 17596661 | Promoter for the specific expression of genes in cells expressing glial fibrillary acidic protein | December 2021 | January 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17619815 | VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | December 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17549492 | GENE INVOLVED IN SYNTHESIS OF CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND USING THE SAME, AND TRANSFORMANT COMPRISING THE SAME | December 2021 | January 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17548345 | CONJUGATE FOR IMMUNODETECTION BASED ON LATERAL FLOW ASSAY, AND IMMUNODETECTION METHOD USING SAME | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17545963 | ENZYME-CATALYZED METHOD FOR SYNTHESIZING (2S, 3R)-2-SUBSTITUTED AMINOMETHYL-3-HYDROXYBUTYRATE | December 2021 | June 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17617533 | ENGINEERED SUCROSE PHOSPHORYLASE VARIANT ENZYMES | December 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17596180 | SYSTEM AND METHOD FOR COMBATING INFECTIONS DUE TO ANTIBIOTIC INDUCED PATHOGENS | December 2021 | June 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17539414 | METHOD FOR ENZYMATIC PREPARATION OF R-3 AMINOBUTYRIC ACID | December 2021 | June 2024 | Allow | 30 | 1 | 1 | No | No |
| 17615578 | CULTURED MEAT PRODUCT WITH GENETICALLY MODIFIED CELLS | November 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17532751 | PET HYDROLASE HAVING IMPROVED THERMAL STABILITY | November 2021 | April 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17522523 | PROTECTING GROUP CHEMISTRY FOR CLEAN, REDUCTANT-FREE DYEING | November 2021 | May 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17522370 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES | November 2021 | March 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17516424 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | November 2021 | December 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17608021 | STRUCTURE-GUIDED ENGINEERING OF PEPTIDE-BASED NLRP3 INFLAMMASOME INHIBITORS FOR MYELODYSPLASTIC SYNDROMES (MDS) | November 2021 | October 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17607922 | MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED HYDROCARBONS | November 2021 | February 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17511391 | MUTANT PORE | October 2021 | February 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17510641 | BIOSYNTHESIS OF PRODUCTS FROM 1-CARBON COMPOUNDS | October 2021 | April 2025 | Allow | 41 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MEAH, MOHAMMAD Y.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MEAH, MOHAMMAD Y works in Art Unit 1652 and has examined 1,285 patent applications in our dataset. With an allowance rate of 70.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner MEAH, MOHAMMAD Y's allowance rate of 70.9% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MEAH, MOHAMMAD Y receive 1.59 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MEAH, MOHAMMAD Y is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +43.1% benefit to allowance rate for applications examined by MEAH, MOHAMMAD Y. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.3% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 164.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 91% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 94.6% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 73.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.2% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 12.7% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.2% of allowed cases (in the 52% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.